Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Camp4 Therapeutics (CAMP) Cash from Operations (2023 - 2026)

Camp4 Therapeutics recorded quarterly Cash from Operations of 11000000.0 in Q1 2026, down 276.11% quarter-over-quarter from 6246000.0 in Q4 2025, and up 23.0% year-over-year from 8942977.46 in Q1 2025.

Camp4 Therapeutics' Cash from Operations history runs 4 years deep, the most recent figure standing at 11000000.0 for Q1 2026.

  • In Q1 2026, Cash from Operations rose 23.0% year-over-year to 11000000.0; the TTM figure through Mar 2026 stood at 26314000.0 (up 45.97% YoY), while the FY2025 annual figure was 29600000.0, up 35.03% from the prior year.
  • Cash from Operations came in at 11000000.0 for Q1 2026 at Camp4 Therapeutics, down from 6246000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 6246000.0 in Q4 2025 to a low of 14286000.0 in Q1 2025.
  • A 4-year average of 9794500.0 and a median of 11180000.0 in 2024 frame the typical range for Cash from Operations.
  • On a YoY basis, Cash from Operations climbed as much as 155.33% in 2025 and fell as far as 28.21% in 2025.
  • Camp4 Therapeutics' Cash from Operations stood at 11783000.0 in 2023, then gained by 4.2% to 11288000.0 in 2024, then surged by 155.33% to 6246000.0 in 2025, then tumbled by 276.11% to 11000000.0 in 2026.
  • According to Business Quant data, Cash from Operations over the past three periods registered 11000000.0, 6246000.0, and 11217000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Operations (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -1.67 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -12.20 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -2.49 Mn
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 1.43 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 1.08 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 70.50 Mn
10 Camp4 Therapeutics 245.89 Mn 245.89 Mn - -11.00 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -11.00 Mn
Mar 31, 2026 -11.00 Mn
Dec 31, 2025 6.25 Mn
Dec 31, 2025 6.25 Mn
Sep 30, 2025 -11.22 Mn
Sep 30, 2025 -11.22 Mn
Jun 30, 2025 -10.34 Mn
Jun 30, 2025 -10.34 Mn
Mar 31, 2025 -14.29 Mn
Mar 31, 2025 -14.29 Mn
Dec 31, 2024 -11.29 Mn
Dec 31, 2024 -11.29 Mn
Sep 30, 2024 -9.69 Mn
Sep 30, 2024 -9.69 Mn
Jun 30, 2024 -13.44 Mn
Jun 30, 2024 -13.44 Mn
Mar 31, 2024 -11.14 Mn
Mar 31, 2024 -11.14 Mn
Dec 31, 2023 -11.78 Mn
Dec 31, 2023 -11.78 Mn